Article citationsMore>>

J. D. Abad, C. Wrzensinski, W. Overwijk, M. A. de Witte, A. Jorritsma, C. Hsu, L. Gattinoni, C. J. Cohen, C. M. Paulos, D. C. Palmer, J. B. Haanen, T. N. Schumacher, S. A. Rosenberg, N. P. Restifo and R. A. Morgan, “T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model,” Journal of Immunotherapy, Vol. 31, No. 1, 2008, pp. 1-6. doi:10.1097/CJI.0b013e31815c193f

has been cited by the following article:

• TITLE: Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses

  AUTHORS: Kristian M. Hargadon

  KEYWORDS: Melanoma; Tumor Immunotherapy; Dendritic Cell; Tumor Antigen; T Cell; Vaccine; Adoptive Transfer

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.3 No.2A, June 20, 2013

  ABSTRACT: Melanoma is the most aggressive form of skin cancer and accounts for the vast majority of skin cancer-related deaths. Its ability to metastasize quickly, often before diagnosis, makes this cancer difficult to treat with traditional therapies. The identification of anti-melanoma immune responses in patients and the discovery of tumor antigens targeted by these immune responses have paved the way for immunotherapy as a novel approach to treating this cancer. In this review, the major immunotherapies targeting these melanoma tumor antigens are discussed. The advantages and limitations of peptide-, protein-, and gene-based vaccination maneuvers and adoptive cell transfer therapies are emphasized. Recent insights into melanoma immune evasion strategies are also highlighted, with particular focus on how our increasing knowledge of tumor/immune cell interactions is driving the development of novel immunotherapeutic strategies for the treatment of melanoma.